Nirmatrelvir and ritonavir. Information for health professionals

Abstract

The purpose of this publication is to make health professionals aware of the potential benefits and risks of the combination of nirmatrelvir with ritonavir in the treatment of COVID-19, since, compared to other treatments, it may be more effective in preventing hospitalization and it is less risky and easier to administer. The combination is indicated for mild to moderate cases in people with a positive confirmatory test who are at high risk of progression to severe or critical illness and hospitalization. Special attention is paid to potential drug interactions and healthcare professionals are encouraged to notify their national pharmacovigilance body of suspected adverse reactions to this treatment.